durat
natur
immun
gener
respons
infect
unknown
mani
public
health
respons
model
scenario
outbreak
caus
assum
infect
result
immun
respons
protect
individu
futur
infect
ill
amount
time
timescal
protect
critic
determin
futur
impact
pathogen
presenc
absenc
protect
immun
due
infect
vaccin
avail
affect
futur
transmiss
ill
sever
dynam
immun
natur
protect
relev
discuss
surround
therapeut
use
convalesc
sera
well
effort
identifi
individu
protect
immun
review
scientif
literatur
antibodi
immun
coronavirus
includ
well
relat
merscov
human
endem
coronavirus
hcov
review
abstract
identifi
manuscript
relev
area
focu
antibodi
kinet
correl
protect
immunopathogenesi
antigen
divers
crossreact
popul
seropreval
studi
necessari
determin
immun
respons
evid
coronavirus
provid
clue
guid
futur
research
antibodi
respons
vari
differ
type
antibodi
measur
differ
assay
presenc
antibodi
impact
clinic
cours
sever
diseas
crossreact
differ
coronavirus
crossreact
lead
crossprotect
infect
protect
futur
infect
long
immun
last
correl
protect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
introduct
pandem
sever
acut
respiratori
syndrom
coronaviru
current
underway
result
worldwid
sever
morbid
mortal
limit
preexist
immun
viru
thought
respons
explos
increas
case
across
world
nearli
transmiss
model
assum
infect
produc
immun
reinfect
durat
least
one
year
assumpt
relev
public
health
offici
implement
manag
variou
nonpharmaceut
intervent
util
sera
infect
individu
therapeut
abil
serolog
test
identifi
immun
dynam
immun
also
affect
perform
serolog
test
quantifi
extent
infect
popul
howev
knowledg
dynam
natur
immun
respons
infect
limit
scientif
basi
durabl
immun
upon
key
public
health
clinic
strategi
depend
well
develop
sever
author
note
human
experiment
infect
studi
call
human
challeng
studi
suggest
protect
coronaviru
infect
may
last
year
hcov
use
human
challeng
experi
sinc
shortli
discoveri
experi
individu
intent
infect
hcov
provid
clearest
character
human
respons
coronavirus
potenti
immun
respons
limit
infect
diseas
multipl
human
challeng
studi
measur
antibodi
immun
coronaviru
challeng
identifi
antibodi
respons
associ
protect
infect
serolog
respons
symptom
low
sever
hcov
allow
safe
use
virus
human
challeng
experi
greater
likelihood
sever
ill
limit
applic
experi
although
argu
use
subset
popul
durat
immun
dictat
overal
cours
pandem
postpandem
dynam
understand
tempor
dynam
protect
immun
critic
introduct
novel
pathogen
explos
outbreak
across
globe
may
threaten
persist
reduc
number
avail
host
suscept
infect
immun
interact
endem
coronavirus
could
theoret
affect
shortand
longterm
dynam
vice
versa
crossprotect
antibodydepend
enhanc
interact
effect
yet
understood
becom
endem
agestratifi
seropreval
studi
endem
coronavirus
may
provid
estim
incid
rate
presenc
higher
level
popul
immun
describ
result
systemat
review
literatur
antibodi
measur
immun
coronavirus
includ
endem
human
coronavirus
princip
merscov
middl
east
respiratori
syndrom
cov
earli
work
conceptu
stage
exposur
infect
immun
may
play
role
dynam
literatur
describ
work
coronavirus
provid
insight
stage
follow
see
figur
visual
abstract
review
first
exposur
pathogen
gener
immun
respons
chang
time
individu
antibodi
kinet
upon
exposur
infect
histori
might
play
role
provid
protect
new
infect
literatur
provid
evid
correl
protect
challeng
studi
longitudin
cohort
studi
upon
infect
individu
immun
state
possibl
impact
preexist
antibodi
coronavirus
among
mechan
may
caus
harm
immunopathogenesi
literatur
topic
primarili
consist
vitro
experi
correl
immun
risk
immunopathogenesi
complic
exist
multipl
genera
coronavirus
antigen
divers
may
provid
crossprotect
may
also
caus
fals
posit
assay
result
due
crossreact
final
preced
phenomena
individu
level
interact
determin
popul
seropreval
studi
measur
quantiti
across
differ
age
group
provid
evid
albeit
ecolog
evid
propos
mechan
immun
individu
level
conduct
search
pubm
databas
march
use
search
term
coronaviru
follow
term
phrase
serolog
serop
cross
reactiv
complement
fixat
also
search
term
search
term
sar
mer
articl
includ
search
regardless
public
date
articl
includ
electron
aheadofprint
public
avail
pubm
databas
attempt
contact
author
obtain
unpublish
data
abstract
review
two
review
articl
consid
applic
exclud
see
addit
identifi
articl
may
relev
refer
list
articl
identifi
pubm
search
abstract
classifi
studi
antibodi
immun
respons
human
coronaviru
studi
human
coronaviru
antibodi
immun
studi
nonhuman
basic
biolog
studi
virusantibodi
interact
character
actual
human
studi
human
coronaviru
anoth
languag
duplic
anoth
record
dead
linkbad
returnnois
disagr
two
review
classif
resolv
third
review
manuscript
classifi
first
categori
studi
antibodi
immun
respons
human
coronaviru
review
entireti
classifi
one
review
relev
one
follow
antibodi
kinet
correl
protect
antigen
divers
cross
reactiv
immunopathogenesi
andor
popul
seropreval
incid
manuscript
consid
relev
preced
categori
exclud
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
conduct
pool
analys
two
area
data
avail
suffici
compar
includ
singl
analysi
summar
approxim
time
detect
across
studi
two
set
studi
first
set
includ
studi
cumul
number
posit
case
time
addit
posit
case
ad
cumul
curv
assum
new
detect
case
time
point
approxim
cumul
curv
sometim
declin
figur
indic
particip
lost
followup
second
identifi
data
describ
either
seroposit
function
time
measur
antibodi
report
cutoff
data
includ
first
seroposit
time
point
within
three
week
ill
onset
ii
first
estim
neg
subsequ
measur
within
three
week
first
posit
estim
annual
forc
infect
agestratifi
seropreval
data
assum
individu
acquir
infect
singl
strainspecif
forc
infect
constant
time
use
standard
method
individu
becom
seroposit
remain
seroposit
remaind
lifetim
regardless
protect
statu
estim
total
forc
infect
foi
four
major
endem
strain
draw
bootstrap
sampl
four
strainspecif
foi
calcul
sum
across
strain
age
first
infect
given
invers
total
foi
search
identifi
abstract
potenti
relev
figur
two
review
read
abstract
identifi
manuscript
full
review
manuscript
classifi
area
focu
present
find
review
area
focu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
multipl
serolog
assay
use
character
antibodi
respons
coronavirus
assay
encount
review
fell
two
major
categori
tabl
commonli
use
assay
bind
assay
includ
enzym
link
immunosorb
assay
elisa
immunofluoresc
assay
ifa
western
blot
hemagglutin
inhibit
hai
complement
fixat
cf
second
categori
assay
neutral
assay
neutral
assay
typic
consid
gold
standard
measur
function
antibodi
respons
measur
biolog
activ
throughout
viral
replic
process
research
use
assay
type
character
antibodi
activ
antibodi
class
ie
igg
igm
iga
antibodi
known
differ
tempor
dynam
report
specif
class
antibodi
character
figur
character
specifi
report
measur
antibodi
aggreg
across
class
sourc
sampl
review
studi
almost
exclus
serum
sampl
howev
mucos
sampl
collect
swab
nasal
wash
also
report
initi
studi
classifi
relev
antibodi
kinet
relev
associ
antibodi
respons
clinic
sever
select
review
endem
hcov
merscov
includ
nonpeerreview
preprint
tabl
provid
summari
studi
digit
data
subset
studi
includ
suffici
detail
longitudin
antibodi
measur
supplementari
data
file
studi
report
cumul
seroconvers
digit
studi
provid
estim
first
week
onset
symptom
measur
least
one
month
onset
symptom
studi
shortlist
antibodi
respons
infect
coronavirus
rare
report
acut
phase
ill
day
mani
studi
report
immun
respons
character
robust
increment
antibodi
titer
merscov
second
third
week
follow
onset
ill
callow
et
al
found
similar
dynam
iga
igg
across
individu
experiment
infect
antibodi
level
increas
day
peak
around
day
although
signific
variat
patient
report
yang
et
al
analyz
data
across
patient
found
higher
posit
rate
igm
igg
first
month
found
proport
patient
seroconvert
igm
peak
day
onset
follow
gradual
decreas
igm
level
igg
level
peak
week
anoth
studi
infect
patient
detect
seroconvers
igg
igm
iga
similar
time
indic
earliest
reach
peak
averag
day
current
earli
character
antibodi
chang
prolong
period
time
preliminari
studi
analyz
antibodi
chang
recent
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
infect
tan
et
al
found
igm
detect
day
peak
day
across
patient
igg
appear
day
peak
day
patient
zhao
et
al
determin
seroconvers
among
patient
took
place
median
time
igm
igg
neutral
antibodi
day
multipl
studi
report
igm
igg
titer
increas
first
week
follow
symptom
onset
igm
level
gradual
wane
remain
detect
merscov
comparison
igg
level
month
post
followup
studi
examin
antibodi
kinet
extend
period
time
focus
igg
callow
et
al
found
among
experiment
infect
peak
igg
iga
antibodi
level
wane
week
year
post
inocul
similar
level
found
inocul
uninfect
patient
studi
report
detect
igg
level
recov
merscov
patient
respect
five
month
one
year
ill
onset
anoth
detect
igg
antibodi
across
patient
week
endpoint
studi
found
studi
analyz
chang
antibodi
kinet
cours
mani
year
ill
onset
cao
et
al
describ
similar
longterm
dynam
igg
neutral
antibodi
cours
studi
titer
peak
month
wane
thereaft
patient
detect
level
igg
neutral
antibodi
respect
month
studi
increasingli
explor
potenti
link
case
sever
antibodi
respons
howev
avail
inform
analyz
natur
relationship
uneven
across
virus
sever
studi
merscov
well
first
preliminari
analys
explicitli
explor
connect
fewer
studi
endem
hcov
sar
sever
studi
found
case
vari
sever
eg
asymptomat
mild
sever
develop
detect
antibodi
merscov
one
studi
found
rise
antibodi
acut
convalesc
sera
correl
posit
symptom
clinic
score
patient
experiment
infect
tabl
howev
studi
report
symptom
sever
evid
differ
antibodi
respons
among
case
experienc
symptom
differ
sever
inconclus
survivor
sequela
found
lower
neutral
antibodi
patient
without
sequela
although
studi
otherwis
found
signific
differ
kinet
accord
diseas
sever
anoth
studi
found
evid
differ
antibodi
respons
patient
surviv
die
merscov
hand
ko
et
al
found
seroconvers
rate
peak
antibodi
level
increas
diseas
sever
okba
et
al
report
robust
respons
sever
infect
oppos
low
seroconvers
asymptomat
mild
case
milder
infect
also
appear
less
like
elicit
serolog
respons
although
okba
et
al
suggest
seroconvers
detect
may
depend
antibodi
target
sever
case
also
found
slower
respons
patient
die
seroconvert
week
author
hypothes
seroconvers
rate
sever
case
may
associ
prolong
viral
shed
low
antibodi
respons
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
mild
case
may
due
shortliv
infect
anoth
studi
suggest
weaker
antibodi
respons
endem
hcov
specif
might
mainli
infect
upper
respiratori
tract
preliminari
studi
point
possibl
contrast
pattern
merscov
igm
antibodi
appear
time
sever
nonsever
case
igg
appear
sooner
sever
case
hand
neutral
antibodi
titer
higher
sever
case
distribut
time
point
antibodi
detect
see
method
digit
data
shown
figur
median
time
detect
similar
across
differ
antibodi
day
iqr
day
day
iqr
day
longer
merscov
day
iqr
day
sever
appear
associ
time
detect
igm
merscov
case
day
longer
igg
merscov
day
longer
sever
case
data
time
seroconvers
base
symptomat
patient
data
avail
asymptomat
individu
figur
studi
report
symptom
sever
longerterm
data
focus
merscov
studi
report
cutoff
assay
use
two
third
patient
mild
symptom
detect
posit
igg
antibodi
six
month
one
year
patient
sever
symptom
detect
igg
antibodi
point
time
tabl
identif
correl
protect
requir
character
immun
respons
prior
known
exposur
period
risk
infect
ill
outcom
character
review
found
level
detail
present
human
challeng
experi
hcov
identifi
studi
volunt
expos
experiment
infect
hcov
associ
preinfect
antibodi
measur
either
virolog
serolog
ill
outcom
upon
experiment
infect
tabl
earliest
identifi
experiment
infect
studi
coronavirus
found
neutral
titer
excret
viru
experiment
exposur
compar
preexposur
titer
greater
interestingli
studi
one
report
ill
function
dose
viral
inoculum
given
challeng
experi
suggest
given
higher
dose
like
experi
cold
expos
lower
dose
barrow
et
al
found
lower
proport
individu
high
neutral
titer
experienc
signific
cold
upon
viral
challeng
individu
low
titer
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
callow
character
iga
igg
neutral
antibodi
sera
nasal
wash
volunt
experiment
expos
hcov
found
multipl
antibodi
respons
associ
reduc
risk
infect
seroconvers
symptomat
ill
upon
challeng
individu
seroconvert
experiment
viral
exposur
defin
rise
elisa
igg
serum
antibodi
significantli
higher
serum
igg
neutral
antibodi
nasal
iga
serum
mucos
iga
associ
durat
viral
shed
post
experiment
infect
shed
day
statist
significantli
less
mucos
iga
shed
less
day
ngml
versu
ngml
p
serum
neutral
antibodi
found
significantli
associ
viral
shed
durat
studi
also
show
protect
associ
preinfect
serum
neutral
antibodi
serum
igg
nasal
iga
clinic
sever
score
nasal
secret
weight
measur
sever
rhinorrhea
symptom
anoth
prospect
studi
report
detect
preexist
neutral
antibodi
among
medic
student
viru
isol
seroconvers
preexist
neutral
antibodi
invers
associ
increas
neutral
antibodi
reinfect
associ
reinfect
event
determin
cf
seroconvers
sever
studi
expos
volunt
two
challeng
viru
month
apart
reed
rechalleng
volunt
experiment
infect
month
previous
first
challeng
develop
symptom
detect
virus
experienc
signific
rise
titer
second
experienc
ill
detect
viru
signific
rise
titer
callow
et
al
rechalleng
volunt
dose
coronaviru
one
year
apart
volunt
infect
first
exposur
infect
second
exposur
howev
none
individu
develop
respiratori
ill
symptom
experienc
mean
durat
detect
viru
day
compar
mean
initi
challeng
identifi
paper
relat
crossreact
andor
antigen
divers
tabl
studi
identifi
highli
import
describ
text
data
digit
studi
supplementari
data
file
within
coronavirida
famili
coronavirina
subfamili
includ
four
distinct
genera
alphacoronavirus
includ
two
major
human
coronavirus
multipl
strain
also
character
betacoronavirus
categor
lineag
lineag
includ
lineag
b
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
includ
lineag
c
includ
merscov
multipl
bat
coronavirus
lineag
contain
coronavirus
thu
far
identifi
bat
document
caus
common
cold
recent
strain
infect
upper
lower
respiratori
tract
result
sever
rare
fatal
diseas
cov
associ
human
diseas
includ
enter
diseas
infant
zoonot
infect
livestock
seem
rare
describ
coronavirus
four
structur
protein
spike
protein
nucleocapsid
n
envelop
protein
e
membran
protein
protein
protrud
viru
envelop
immunodomin
consist
two
subunit
protein
contain
receptor
bind
domain
rbd
protein
mediat
cell
membran
fusion
nucleocapsid
protein
also
immunogen
smaller
lack
glycosyl
site
induc
antibodi
sooner
infect
make
attract
protein
diagnost
assay
design
sequenc
homolog
n
betacoronavirus
respect
homolog
alphacoronavirus
lower
homolog
n
similar
harbor
sequenc
homolog
n
follow
merscov
respect
individu
experiment
inocul
strain
lp
experienc
rise
neutral
antibodi
lp
individu
inocul
howev
volunt
experiment
inocul
strain
protect
challeng
homolog
strain
one
year
none
shed
viru
show
symptom
rise
antibodi
volunt
experienc
partial
protect
heterolog
strain
protect
increas
popul
immun
popul
associ
less
clinic
diseas
upon
challeng
strain
studi
serolog
respons
hcov
n
protein
point
crossreact
within
alphahcov
betahcov
alphaand
betahcov
consist
observ
human
challeng
studi
children
experienc
natur
hcov
infect
experi
seroconvers
either
simultan
howev
longitudin
studi
newborn
found
children
seroconvert
either
although
virus
alphahcov
later
studi
newborn
follow
age
month
show
asymmetr
interact
within
alphahcov
betahcov
seroconvers
observ
recent
seroconvers
recent
infect
suggest
provid
least
shortterm
protect
immun
similarli
seroconvers
occur
prior
rare
suggest
protect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
individu
experienc
natur
infect
detect
antibodi
acut
convalesc
sampl
n
protein
ifa
neutral
healthi
individu
antibodi
endem
hcov
rare
detect
antibodi
bound
infect
cell
n
protein
n
n
protein
subset
site
share
homolog
potenti
explain
lowlevel
fals
posit
result
nbase
assay
sar
patient
often
experi
rise
antibodi
andor
pair
acuteconvalesc
sampl
one
studi
number
sar
patient
experienc
rise
bind
antibodi
greater
sar
patient
also
show
rise
antibodi
n
protein
among
patient
detect
ifa
titer
merscov
antimerscov
neutral
antibodi
subset
avail
pair
sampl
experienc
seroconvers
limit
seroconvers
alphacov
studi
anim
handler
wildlif
market
guangzhou
lowlevel
preval
antibodi
ifa
nt
detect
antibodi
toward
merscov
followup
studi
found
crossreact
merscov
unlik
due
similar
receptorbind
domain
rbd
monoclon
antibodi
mab
rais
rbd
bind
merscov
rbd
neutral
merscov
even
high
concentr
merscov
may
produc
less
crossreact
subset
slaughterhous
worker
saudi
arabia
antibodi
merscov
ifa
well
pandem
hcov
none
reactiv
spike
protein
merscov
patient
observ
lowlevel
crossreact
one
studi
n
protein
crossreact
research
develop
diagnost
assay
truncat
n
protein
see
figur
associ
homolog
heterolog
titer
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
studi
strain
zoonot
phase
palm
civet
bat
earli
late
sar
epidem
reveal
escap
neutral
mab
target
spike
rbd
sera
balbc
mice
immun
full
length
protein
civet
strain
ineffect
human
vice
versa
despit
signific
crossreact
mab
conform
epitop
rbd
multipl
mutat
differ
singl
mutat
shown
disrupt
neutraliz
contrast
mab
target
region
critic
fusion
entri
protein
immunogen
broadli
neutral
strain
recent
studi
show
reduc
bind
mab
sar
patient
rbd
especi
block
bind
receptor
mab
potent
bound
rbd
protein
compet
rbd
bind
receptor
suggest
bound
differ
conserv
site
protein
similar
studi
conduct
studi
chang
merscov
five
recombin
rbd
protein
construct
mutat
detect
merscov
strain
isol
human
camel
rbd
maintain
function
induc
potent
neutral
antibodi
residu
receptor
bind
motif
mutat
evad
neutral
crossreact
persist
bind
affin
main
receptor
merscov
lost
suggest
limit
antigen
escap
merscov
studi
merscov
isol
distinct
amino
acid
differ
replic
protein
found
differ
replic
kinet
clear
attribut
differ
initi
review
paper
identifi
relat
immunopathogenesi
found
suffici
relev
review
tabl
detail
summar
figur
multipl
studi
suggest
possibl
preexist
antibodi
increas
diseas
facilit
viral
entri
cell
mechan
long
hypothes
explan
sever
dengu
infect
call
antibodydepend
enhanc
ade
also
hypothes
relev
coronavirus
specif
patient
seroconvert
earli
infect
reason
individu
mount
respons
quickli
other
unknown
correl
greater
age
earli
respons
higher
titer
suggest
prime
effect
exist
antibodi
endem
strain
author
anoth
studi
point
toward
enhanc
antibodi
within
episod
nasopharyng
viral
load
increas
first
week
declin
thereaft
clinic
worsen
seen
mani
patient
week
two
viru
shed
stool
urin
observ
toward
end
mani
manifest
newappear
lesion
origin
lesion
improv
time
appear
new
lesion
correl
igg
seroconvers
suggest
patholog
post
week
one
driven
immun
respons
rather
uncontrol
viral
replic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
other
argu
ade
due
neutral
antibodi
unlik
treatment
convalesc
serum
result
advers
effect
observ
increas
risk
diseas
infant
midlevel
matern
antibodi
dengu
compar
high
low
level
matern
antibodi
import
evid
support
role
antibodi
pathogenesi
dengu
similar
mechan
identifi
seroposit
seroneg
kitten
infect
felin
infecti
periton
viru
coronaviru
caus
fatal
diseas
cat
one
studi
character
endem
hcov
infant
observ
highest
lower
respiratori
tract
infect
burden
month
age
month
close
none
year
upper
respiratori
tract
infect
burden
close
uniform
heighten
diseas
burden
matern
immun
wane
medium
level
lower
tract
absenc
observ
upper
tract
antibodi
circul
subtli
support
possibl
ade
hcov
regard
region
spike
protein
may
induc
antibodi
enhanc
effect
mab
show
mild
moder
effect
one
particular
clone
show
neutral
effect
seen
antin
mab
limit
evid
mechan
causal
inflammatori
gene
express
differ
among
patient
differ
sever
link
antibodi
presenc
enhanc
sever
via
infect
immun
cell
remain
unclear
suspect
role
autoreact
respons
increas
sever
ill
prolong
tissu
destruct
increas
present
host
protein
tor
bcell
result
adapt
respons
self
ie
epitop
spread
igg
antibodi
target
uninfect
lung
epitheli
cell
detect
patient
twenti
day
postsymptom
onset
reactiv
seen
serum
healthi
individu
pneumonia
patient
complement
inactiv
show
cytotox
effect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
igg
presentunbound
presenc
antibodi
also
increas
bind
immun
cell
pbmc
cell
treat
ifn
replic
condit
cytokin
storm
would
observ
separ
studi
demonstr
coloc
ab
collect
serum
sar
patient
day
postfev
onset
annexin
immunoprecipit
annexin
cell
surfac
elev
express
annexin
surfac
stimul
ifn
cytokin
induc
turn
increas
bind
ab
cell
howev
pathogen
role
explor
altern
similar
viral
host
epitop
molecular
mimicri
gener
crossreact
antibodi
mice
human
evid
antin
antibodi
cross
react
antiinflammatori
cytokin
express
mani
tissu
includ
lung
bone
marrow
author
suggest
high
antin
antibodi
induc
rel
earli
infect
may
involv
thrombocytopenia
lymphopenia
observ
earli
infect
paper
review
paper
classifi
data
age
seropreval
seroincid
studi
confirm
review
digitiz
data
age
rang
across
studi
sampl
size
studi
rang
studi
endem
hcov
tabl
supplementari
data
file
contain
detail
studi
endem
coronavirus
seropreval
rise
sharpli
childhood
littl
chang
seropreval
age
among
adult
exact
dynam
month
year
vari
studi
gener
trend
remain
consist
figur
display
hcov
ageseropreval
curv
paper
digitiz
data
seropreval
age
panel
repres
four
major
endem
strain
trend
paper
display
figur
larg
two
studi
show
mark
declin
seropreval
age
avail
data
set
spars
incid
pattern
inconsist
studi
figur
display
ageincid
curv
paper
digitiz
data
incid
age
panel
repres
two
strain
includ
studi
increas
trend
seroincid
age
outbreak
tecumseh
michigan
similar
analysi
seroincid
outbreak
show
increas
longitudin
followup
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
famili
seattl
found
lower
rate
seroconvers
among
adult
compar
children
comparison
cohort
yearold
cohort
yearold
found
clear
differ
incid
two
age
group
measur
seroconvers
pcrconfirm
hcovassoci
respiratori
ill
final
observ
studi
shown
evid
coronavirusassoci
respiratori
ill
elderli
popul
across
age
forc
infect
endem
coronaviru
strain
high
age
first
infect
low
variabl
across
studi
simpl
catalyt
model
fit
digit
data
predict
median
total
forc
infect
across
studi
ci
see
tabl
estim
studi
correspond
averag
age
first
infect
strain
year
ci
cohort
infant
follow
birth
averag
two
year
experienc
annual
strainspecif
incid
rate
zhou
et
al
serosurvey
measur
igg
igm
separ
show
differ
pattern
age
figur
igg
seropreval
rose
high
level
age
remain
high
adult
popul
igm
seropreval
declin
zero
individu
age
older
author
interpret
evid
first
infect
occur
age
strain
rapid
rise
seropreval
age
observ
literatur
suggest
forc
infect
thu
proport
seroposit
serotyp
older
age
high
enough
preclud
signific
rate
coronaviru
infect
among
older
adult
serotyp
confer
lifelong
homolog
immun
figur
green
dot
line
hand
shortterm
complet
immun
lifelong
partial
immun
exist
multipl
genotyp
within
singl
serotyp
limit
crossimmun
could
explain
ageseropreval
ageincid
curv
seen
literatur
figur
review
gave
rise
sever
observ
either
consist
conflict
across
paper
studi
enrol
children
less
month
detect
loss
matern
antibodi
repres
preliminari
line
defens
newborn
children
studi
show
discern
differ
ageseropreval
trend
overal
seropreval
strain
gao
et
al
found
seropreval
significantli
lower
seropreval
addit
chan
et
al
found
seropreval
low
year
old
hong
kong
state
expect
low
rate
among
respiratori
ill
final
studi
measur
presenc
bind
antibodi
blood
studi
figur
cavallaro
monto
red
measur
seroposit
use
neutral
assay
seropreval
markedli
lower
studi
compar
other
could
indic
lower
test
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
sensit
compar
modern
test
lack
correl
neutral
bind
antibodi
endem
coronavirus
regard
novel
coronavirus
serosurvey
confirm
rate
asymptomat
subclin
infect
low
asymptomat
subclin
rate
merscov
gener
higher
avail
serosurvey
lack
power
draw
strong
infer
age
trend
larg
serosurvey
conduct
across
saudi
arabia
found
age
seroposit
individu
significantli
lower
age
clinic
case
anoth
conduct
across
multipl
countri
africa
asia
found
trend
seropreval
age
studi
risk
factor
within
camel
worker
either
address
age
risk
factor
found
associ
present
broad
comprehens
review
multipl
aspect
literatur
antibodi
immun
coronavirus
identifi
number
key
find
median
time
detect
similar
across
differ
antibodi
day
iqr
day
day
iqr
day
longer
merscov
day
iqr
day
longterm
studi
found
igg
wane
time
typic
detect
least
year
other
found
detect
level
igg
three
year
post
symptom
onset
antibodi
kinet
vari
across
sever
gradient
longer
durat
detect
antibodi
associ
sever
symptom
human
challeng
studi
hcov
indic
serum
mucos
immun
respons
serum
igg
iga
neutral
titer
mucos
iga
provid
possibl
correl
protect
infect
diseas
howev
repeat
human
challeng
experi
singl
hcov
suggest
individu
infect
hcov
one
year
first
challeng
possibl
lower
sever
crossreact
within
minim
reactiv
alphaand
betacov
endem
hcov
rare
induc
crossreact
antibodi
emerg
hcov
merscov
stimul
antibodi
induc
prior
hcov
infect
multipl
mechan
immunopatholog
suggest
strong
causal
evid
exist
extent
presenc
antibodi
affect
human
diseas
sever
known
seropreval
four
major
endem
hcov
strain
rose
rapidli
childhood
remain
high
adult
median
age
first
infect
strain
year
ci
clear
trend
seroincid
age
mani
studi
demonstr
incid
coronaviru
infect
elderli
popul
result
suggest
measur
impact
immun
coronavirus
futur
risk
protect
may
transient
suggest
set
search
term
identifi
relev
work
other
may
expand
search
due
speed
new
research
produc
limit
systemat
review
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
paper
march
evid
immun
respons
like
contain
work
sinc
publish
exclud
review
anim
studi
studi
anim
cov
remain
humanfocus
literatur
like
relev
area
review
limit
scope
review
antibodymedi
immun
mean
understand
area
review
may
incomplet
final
digit
data
could
affect
public
bia
select
bia
mean
might
repres
data
studi
aim
pool
analys
summar
array
studi
rather
formal
explor
hypothes
result
model
use
simpl
exampl
estim
forc
infect
agestratifi
seropreval
data
consid
featur
model
assay
sensit
timeand
agevari
forc
infect
serorevers
crossreact
strain
might
better
explain
pattern
seen
data
need
develop
serolog
assay
high
sensit
screen
suffici
specif
exclud
individu
unneed
intervent
evid
previou
emerg
cov
suggest
fals
neg
like
result
wane
antibodi
level
studi
antibodi
kinet
symptomat
patient
kinet
subclin
infect
signific
proport
infect
remain
key
gap
literatur
indic
less
sever
ill
associ
reduc
antibodi
respons
suggest
mild
case
may
pose
challeng
serolog
assay
end
propos
polici
immun
passport
allow
individu
presum
immun
return
work
social
distanc
measur
relax
requir
highli
specif
serolog
test
mitig
advers
outcom
evid
past
emerg
hcov
suggest
low
fals
posit
crossreact
endem
hcov
howev
antibodi
titer
necessarili
translat
immun
challeng
studi
indic
multipl
candid
may
serv
correl
protect
includ
serum
mucos
measur
howev
need
specif
evalu
knowledg
gap
correl
protect
durabl
must
fill
immun
passport
safe
gener
use
pharmaceut
intervent
protect
suscept
individu
improv
outcom
among
sick
individu
first
need
test
random
trial
vaccin
variou
antigen
current
develop
polyclon
antibodi
patient
use
case
treatment
though
evid
immunopathogenesi
remain
limit
import
design
rigor
trial
provid
valid
evid
posit
effect
also
detect
neg
effect
occur
associ
adapt
stop
criteria
concern
might
extend
beyond
vaccin
develop
neg
effect
subtl
weakli
detect
phase
iii
studi
event
mass
vaccin
follow
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
success
efficaci
studi
surveil
design
detect
wane
immun
advers
event
due
vaccinemedi
immunopathogenesi
critic
key
question
longterm
dynam
includ
whether
like
erad
whether
widespread
immun
lead
transient
decreas
incid
long
take
anoth
larg
outbreak
occur
model
studi
crucial
answer
question
reli
understand
immun
respons
interact
coronavirus
make
relev
predict
analysi
dataset
specif
serosurvey
need
account
kinet
wane
immun
effect
imperfect
assay
draw
meaning
infer
final
note
best
evid
immun
respons
come
studi
viru
studi
perform
report
unpreced
speed
absenc
firm
evid
mani
turn
exist
coronavirus
model
end
produc
review
aid
research
understand
scope
evid
immun
respons
coronavirus
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
tabl
summari
serolog
assay
tabl
summari
studi
kinet
antibodi
immun
infect
associ
antibodi
respons
diseas
sever
tabl
sever
rate
use
studi
correspond
standardis
tabl
summari
studi
correl
antibodi
immun
protect
cov
infect
tabl
summari
studi
antigen
divers
crossreact
supplementari
data
data
digit
antibodi
kinet
associ
antibodi
respons
clinic
sever
supplementari
data
data
digit
popul
seropreval
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
report
number
individu
experienc
symptom
given
sever
signific
antibodi
rise
post
infect
result
merscov
taken
across
studi
cutoff
assay
use
provid
give
number
patient
igg
level
respect
cutoff
differ
time
point
also
see
figur
exampl
week
patient
mild
symptom
studi
report
cutoff
patient
igg
level
cutoff
merscov
data
digitis
six
studi
figur
aspect
antibodi
respons
includ
review
figur
show
area
focu
review
within
conceptualis
stage
exposur
infect
believ
antibodi
mediat
immun
may
play
role
dynam
individu
level
left
antibodi
respons
follow
first
infectionexposur
increas
declin
antibodi
kinet
sometim
later
individu
may
expos
may
protect
infect
acquir
immun
correl
protect
acquir
immun
may
also
moder
sever
infect
possibl
preexist
immun
may
lead
immunopathogenesi
relev
first
second
exposur
individuallevel
dynam
aggreg
form
populationlevel
seropreval
righttop
measur
seropreval
may
imperfectli
measur
past
exposur
infect
due
antigen
divers
futur
virus
crossreact
endem
human
coronavirus
hcov
measur
seropreval
may
also
inconsist
across
time
antibodieslevel
within
individu
wane
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
diagrammat
summari
evid
support
red
contradict
blue
contribut
antibodi
pathogenesi
antibodi
trigger
upon
infect
may
facilit
entri
immun
cell
later
stage
infect
concentr
low
replic
happen
viru
releas
consequenti
induct
cytokin
inconclus
occur
associ
sever
diseas
role
antin
antibodi
support
bind
observ
item
shown
grey
weaker
evid
given
specul
literatur
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
western
blot
ns
figur
ageseropreval
curv
studi
appropri
digitiz
data
endem
hcov
color
denot
studi
point
type
denot
assay
antibodi
measur
data
sarateanu
et
al
averag
two
serosurvey
conduct
data
liang
et
al
measur
cord
blood
sampl
adult
age
repres
chang
seropreval
across
childhood
therefor
connect
two
point
line
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
seropreval
shade
area
scale
indic
right
yaxi
seroincid
line
scale
indic
left
yaxi
curv
age
singl
strain
four
hypothet
model
coronaviru
immun
complet
homolog
immun
model
complet
homolog
immun
year
revers
full
suscept
model
partial
homolog
immun
life
first
infect
model
genotyp
within
strain
confer
lifelong
genotypespecif
immun
withinstrain
crossimmun
model
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
